Anti-proliferation and radiosensitization effects of chitooligosaccharides on human lung cancer line HepG2

Han, Fushi; Cui, Bo-Han; You, Xiaofang; Xing, Yanfen; Sun, Xiaochun

doi:10.1016/j.apjtm.2015.07.025

Cited by 15 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concentrations of SCFAs and the abundances of Lactobacilli and Bifidobacteria were significantly increased in the cecum of mice treated with COS (Pan et al, 2009). COS are also effective against various cancer cells in vitro , such as prostate, lung, hepatocellular, gastric and colon cancer cells (Park et al, 2011; Han et al, 2015, 2016; Ryu et al, 2017). However, the relationship between the anti-tumor activities of COS and its effects on bacteria in vivo remains unclear.…”

Section: Introductionmentioning

confidence: 99%

Chitooligosaccharides Prevents the Development of Colitis-Associated Colorectal Cancer by Modulating the Intestinal Microbiota and Mycobiota

et al. 2019

Front. Microbiol.

View full text Add to dashboard Cite

Gut microbes play a crucial role in the development of colorectal cancer. Chitooligosaccharides (COS), are oligomer that are depolymerized from chitosan and possess a wide range of biological activities. In this study, the effects of COS on colorectal cancer (CRC) development were evaluated using azoxymethane and dextran sulfate sodium (AOM/DSS) induced mouse model of CRC (CACM). In the COS-treated CRC group (CMCOS), COS protected mice from CRC by decreasing the disease activity index, tumor incidences and multiplicity, and the mRNA levels of COX-2, IL-6, TNF-α, IL-1β, IL-10, and IKK-β mRNA in colonic epithelial cells. The results of a cage-exchanged experiment, in which mice from the CACMe and CMCOSe treatments exchanged cages every day to interact with microbes, showed that gut microbes play an important role in preventing CAC by COS. The abundances of fecal bacteria (total bacteria, Lactobacillus, Enterococcus, Fusobacterium nucleatum and butyrate-producing bacteria) were detected by qPCR on the 0th, 1st, 3rd, 6th, 9th, and 10th weekends. Furthermore, microbiota and mycobiota were analyzed by high-throughput sequencing on an Illumina MiSeq PE300 system. COS protected mice from CRC by reversing the imbalance of bacteria and fungi, especially by reducing the abundance of Escherichia–Shigella, Enterococcus, and Turicibacter, and increasing the levels of Akkermansia, butyrate-producing bacteria and Cladosporium.

show abstract

Section: Introductionmentioning

confidence: 99%

Chitooligosaccharides Prevents the Development of Colitis-Associated Colorectal Cancer by Modulating the Intestinal Microbiota and Mycobiota

et al. 2019

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…COS have been reported to possess a range of beneficial biological effects, including antimicrobial, antioxidant, anti-inflammatory, immunostimulatory, and the inhibition of tumor proliferation [ 7 , 8 , 9 ]. COS suppress the growth of various cancer cells in vitro, such as prostate, lung, hepatocellular, and colon cancer [ 10 , 11 , 12 ]. In vivo, COS have been shown to inhibit tumor growth of HepG2 xenografts, and in a Lewis lung carcinoma (LLC)-bearing mouse model, COS inhibited tumor growth as well as the development of lung metastasis [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC)

et al. 2022

View full text Add to dashboard Cite

The antitumor activity of chitooligosaccharides has been suggested. This phase 2 trial evaluated the efficacy and safety of T-ChOS™, in addition to adjuvant chemotherapy, in patients after resection of pancreatic ductal adenocarcinoma (PDAC). In this single-center, randomized, double-blind, placebo-controlled trial using patients ≥18 years of age after complete macroscopic resection for PDAC, patients were randomly assigned (1:1) to either a continuous oral T-ChOS group or a placebo group, in combination with gemcitabine (GEM) and oral capecitabine (CAP), for a maximum of six cycles. The primary endpoint was disease-free survival (DFS). Recruitment was stopped prematurely in July 2018, with 21 of planned 180 patients included, due to poor accrual and because modified FOLFIRINOX replaced GEM/CAP for the target population. Nine patients received T-ChOS and twelve received the placebo. The median DFS was 10.8 months (95% CI 5.9–15.7) for the T-ChOS arm and 8.4 months (95% CI 0–21.5) in the placebo arm. Overall, seven patients (78%) in the T-ChOS arm and eight patients (67%) in the placebo arm experienced at least one grade 3–4 treatment-related adverse event, most frequently neutropenia. Altogether, the addition of T-ChOS to chemotherapy in patients after resection of PDAC seems safe. However, the clinical benefit cannot be assessed due to the premature cessation of the trial.

show abstract

“…Due to their non-toxic character and solubility in water, their applicability has been investigated in different areas, such as in agriculture, medicine, and pharmacy [ 13 , 14 ]. In addition, studies indicate that COS have multiple biological properties, such as anti-inflammatory, immunostimulant, antimicrobial, antitumor, antidiabetic, antioxidant, and neuroprotective effects [ 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 ]. With regard to their healing activity, different in vitro and in vivo studies demonstrate the potential of COS; however, most of these reports consist of the evaluation of these substances together with other products and few have described their action in animal healing trials [ 24 , 25 ].…”

Section: Introductionmentioning

confidence: 99%

Production and Characterization of Chitooligosaccharides: Evaluation of Acute Toxicity, Healing, and Anti-Inflammatory Actions

Andrade

Araújo

Torres-Rêgo

et al. 2021

IJMS

View full text Add to dashboard Cite

The search for promising biomolecules such as chitooligosaccharides (COS) has increased due to the need for healing products that act efficiently, avoiding complications resulting from exacerbated inflammation. Therefore, this study aimed to produce COS in two stages of hydrolysis using chitosanases derived from Bacillus toyonensis. Additionally, this study aimed to structurally characterize the COS via mass spectrometry, to analyze their biocompatibility in acute toxicity models in vivo, to evaluate their healing action in a cell migration model in vitro, to analyze the anti-inflammatory activity in in vivo models of xylol-induced ear edema and zymosan-induced air pouch, and to assess the wound repair action in vivo. The structural characterization process pointed out the presence of hexamers. The in vitro and in vivo biocompatibility of COS was reaffirmed. The COS stimulated the fibroblast migration. In the in vivo inflammatory assays, COS showed an antiedematogenic response and significant reductions in leukocyte migration, cytokine release, and protein exudate. The COS healing effect in vivo was confirmed by the significant wound reduction after seven days of the experiment. These results indicated that the presence of hexamers influences the COS biological properties, which have potential uses in the pharmaceutical field due to their healing and anti-inflammatory action.

show abstract

Anti-proliferation and radiosensitization effects of chitooligosaccharides on human lung cancer line HepG2

Abstract: COS can inhibit the proliferation of HepG2 cells, and enhance the radiosensitization of HepG2 cells, induce apoptosis and G2/M phase arrest.

Cited by 15 publications

References 29 publications

Chitooligosaccharides Prevents the Development of Colitis-Associated Colorectal Cancer by Modulating the Intestinal Microbiota and Mycobiota

Chitooligosaccharides Prevents the Development of Colitis-Associated Colorectal Cancer by Modulating the Intestinal Microbiota and Mycobiota

A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC)

Production and Characterization of Chitooligosaccharides: Evaluation of Acute Toxicity, Healing, and Anti-Inflammatory Actions

Contact Info

Product

Resources

About